Page values for "Oxycodone"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Oxycodone (hydrochloride)
brand	`String`	OxyContin (ER), Roxicodone (IR), Oxaydo (IR abuse-deterrent), Xtampza ER (abuse-deterrent ER)
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Opioid analgesics\|Opioid analgesic (semi-synthetic)]] • [[:Category:Schedule II controlled substances\|Schedule II controlled substance]] • [[:Category:Analgesics\|Analgesic]]
mechanism	`String`
uses	`String`	'"`UNIQ--vote-00000019-QINU`"', '"`UNIQ--vote-0000001A-QINU`"', '"`UNIQ--vote-0000001B-QINU`"', '"`UNIQ--vote-0000001C-QINU`"'
starting_dose	`String`	IR opioid-naive: 5-10 mg PO every 4-6 hours as needed. ER opioid-naive: '''10 mg PO every 12 hours (lowest available)'''; titrate slowly to clinical effect
preparations	`String`	IR tablets 5, 7.5, 10, 15, 20, 30 mg; IR oral solution 5 mg/5 mL; concentrated solution 20 mg/mL; OxyContin ER tablets 10, 15, 20, 30, 40, 60, 80 mg; Xtampza ER capsules
fda_max	`String`	No fixed ceiling; titrate to clinical effect and tolerability with CDC opioid prescribing guidance constraints on morphine-milligram-equivalent (MME) totals
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	10-30 minutes (IR)
duration	`String`	4-6 hours (IR); 12 hours (ER)
halflife	`String`	3-5 hours (IR); 4.5 hours (ER)'"`UNIQ--ref-0000001D-QINU`"'
bioavailability	`String`	~60-87% (oral; high and more consistent than codeine or hydrocodone, making efficacy less CYP2D6-genotype-dependent)'"`UNIQ--ref-0000001E-QINU`"'
pregnancy	`String`	Chronic third-trimester exposure produces neonatal opioid withdrawal syndrome and respiratory depression at delivery.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Schedule II\|Schedule II controlled substance]] in US'"`UNIQ--ref-0000001F-QINU`"'